Heat shock proteins and cancer therapy: The trail grows hotter! by Repasky, Elizabeth A. & Subjeck, John R.
www.impactjournals.com/oncotarget/  Oncotarget, June, Vol.2, No 6
Oncotarget 2011; 2:  433 - 434 www.impactjournals.com/oncotarget 433
Heat shock proteins and cancer therapy: The trail grows hotter!
Elizabeth A. Repasky  and John R. Subjeck
Commentary On: Neznanov et al, Oncotarget, 2011, 2, 209-21
The physiological properties of the heat shock 
response were initially studied over three decades ago in 
Drosophila based on the observation that it had protective 
functions against teratogenic agents and heat induced 
animal death. While initially believed to be unique to 
flies, it was rapidly observed to be universal response 
common to all living organisms. Early mammalian studies 
(reviewed in ref. [1]) focused on the physiological role of 
heat shock proteins or HSPs in protecting the organism 
against  heat,  a  phenomenon  called  thermotolerance.  It 
was determined that HSPs were able to protect cellular 
proteins and therefore cells from proteotoxic stress such 
as heat shock. This general function of HSPs are not 
restricted to stress protection, but is an essential element 
in the natural operation of cellular machinery which can 
also lead to protein damage under non-stress conditions 
in a protein concentrated intracellular environment. Such 
interactions of the HSP with cellular proteins would 
protect the substrate protein from the damaging effects of 
heat and other proteotoxic conditions as well as to aid in 
the clearance of some damaged proteins via degradation. 
In cancer research, HSPs were initially perceived to play 
a role protecting tumors from hyperthermia when applied 
in multiple treatments, i.e. HSPs induced initially would 
protect the tumor from later treatments [2]. It took many 
more years to begin to appreciate that there are other and 
potentially more significant roles for HSPs in cancer. For 
example,  it  was  recognized  long  ago  that  interference 
with HSP90, could revert tumor cells from a transformed 
to a normal phenotype due to the role of HSP90 in 
facilitating the functions of tyrosine kinases necessary in 
cell transformation. The ability to block HSP90 function 
has since been aggressively pursued as a cancer therapy 
using  specific  HSP90  inhibitors  such  as  geldanamycin 
[3]. Later studies revealed the additional and more 
general role for HSPs in cancer. All proliferating cells 
require an increase in HSP chaperone concentrations due 
to an increase in macromolecular activities that occur 
compared to quiescent cells. This increase in activity can 
be expected to lead to an increase in various phenomena 
such as free radical formation and related protein damage 
in proliferating cells. In addition to this, the increased 
accumulation of mutated proteins expected in cancer also 
poses a further likelihood for cell damage compared to 
normal cells. Combined, these phenomena can result in 
the protein damage signals leading to the enhanced heat 
shock response and HSP levels, protecting the cancer cells 
from the accumulation of misfolded proteins. Thus, cancer 
cells can have an already activated heat shock response, at 
least in part, relative to normal cells. While a heat shock 
response can be robust, the pre-stress activated response 
in cancer suggests that cancer cells would be less capable 
of mounting a further strong response relative to normal 
cells.  Therefore,  additional  proteotoxic  stress  such  as 
hyperthermia may be more toxic to cancer cells relative to 
normal cells. A new paper by Neznanov et al [4] examines 
this hypothesis. It proposes that that proteotoxic stress 
such as hyperthermia might be more effective in killing 
cancer relative to normal tissues since a level of heat shock 
response is already partially occupied in cancer cells. 
Neznanov et al examined the combinations of three forms 
of proteotoxic stress, such as hyperthermia, puromycin 
treatment,  and  bortezomib  treatment  (which  blocks 
protein degradation thereby increasing the accumulation 
of damaged proteins that would otherwise be eliminated). 
They show that these treatments caused substantial control 
of multiple myeloma cell growth, in vitro and in vivo. 
The increased cell death in cancer cells was found to be 
largely due to a p53-independent apoptotic process. This 
study provides tantalizing evidence that cancer cells are 
already addicted to the heat shock response for their own 
survival as hypothesized. The same group has previously 
used another approach to achieve a similar outcome. They 
have demonstrated that the inhibition of HSP expression 
or function through either inhibitors of the transcription 
factor heat shock factor 1or inhibitors of HSP70 function 
can also be toxic to cancer cells, again based on the same 
rationale, i.e. the enhanced need for HSPs in cancer cells 
[5]. Therefore the heat shock response has important 
survival functions in the development and progression of 
cancer. Importantly, studies from the Calderwood group 
also connect the heat shock response with carcinogenesis 
[6]. This information introduces new targets to exploit in 
cancer therapy. It is uplifting to see the very early and 
pioneering studies on the protective functions of HSPs in 
Drosophila being now applied to cancer therapy. 
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